Global Erythropoietin Drug Market Research Report Forecast to 2023

Global Erythropoietin Drug Market Research Report Forecast to 2023

ID: MRFR/Pharma/0852-HCRR | July, 2017 | Region: Global | 85 pages | Half-Cooked Research Reports

Global erythropoietin drug market research report, by product type (biosimilars, first generation formulation and second generation formulation) by application (oncology, renal diseases, HIV and other) and by end user (hospitals and pharmacy) - Forecast Till 2023



Study Objectives
global erythropoietin drug market



  • Detail information about the factors affecting the growth of the global erythropoietin drug

  • Detail analysis of parent market with respect to all the possible segmentation of the market.

  • Detail analysis of emerging key players for the market with their effective strategies.

  • Detail Information about the present and forecasted market and factors that influences the market on global scale.

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global erythropoietin drug market.

  • Analysis of the market of the different factors like- price analysis, supply chain analysis, porters five force analysis etc.

  • Detail information on the possible segments and sub segments of the market. And regional analysis of the market- North America, Europe, Asia Pacific and Middle East and Africa.

  • Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

  • Detail information on trends and the opportunities in various regions.



Intended Audience


  • Pharmaceutical companies

  • Research and Development (R&D) Companies

  • Government and Independent Research Laboratories

  • Contract Research Organizations (CROs)

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Figure 1-
Global erythropoietin drug market, by region

.



Market Scenario:


Erythropoietin drugs are also known as hematopoietin. It is a glycoprotein hormone that controls erythropoiesis or production of RBC. They are used in treatment of different diseases like cancer, chronic renal diseases, AIDS, anaemia and many more. Global erythropoietin market is driven by increasing prevalence of diseases like cancer, AIDA and renal diseases. Beside this introduction of new drugs and different government initiatives for research are also has synergistic effect on growth of the market. Whereas high cost of treatment and side effects of the treatment may restrain the growth of market.


Global erythropoietin drug market is expected to grow at a CAGR of 9.5% during forecasted period.



Segmentation


Global erythropoietin drug market is segmented on the basis of type of product into biosimilars, first generation formulation and second generation formulation. On the basis of application market is segmented as oncology, renal diseases, HIV and other and on the basis of end user they are segmented into hospital and pharmacy.



Regional Analysis


On regional basis, global erythropoietin drug market, North America contribute the largest market which is followed by Europe. Due to continuously increasing cancer population and patient suffering from renal diseases in North America helped to grow this market in North America. Beside this technological advance and governmental initiatives for research has provided fuel for the growth of the market. Asia Pacific is the third largest market and is the fastest growing market for erythropoietin drug market. While Middle East and Africa has the least contribution in global erythropoietin drug market.



Key players for
global erythropoietin drug market
Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Amgen (US), Kyowa Hakko Kirin, Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (US), Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), 3SBio, Boehringer Ingelheim (US), BIOSIDUS (Argentina).


Market Assessment




The report for
global erythropoietin drug market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

1    INTRODUCTION    

      1.1    DEFINITION    

      1.2    SCOPE OF STUDY    

            1.2.1    RESEARCH OBJECTIVE    

            1.2.2    ASSUMPTIONS & LIMITATIONS    

                1.2.2.1    ASSUMPTIONS    

                1.2.2.2    LIMITATIONS    

      1.3    MARKET STRUCTURE:    

2    RESEARCH METHODOLOGY    

      2.1    RESEARCH PROCESS:    

      2.2    PRIMARY RESEARCH    

      2.3    SECONDARY RESEARCH:    

3    MARKET DYNAMICS    

      3.1    DRIVERS    

      3.2    RESTRAINTS        

      3.3    OPPORTUNITIES    

      3.4    MACROECONOMIC INDICATORS    

4    MARKET FACTOR ANALYSIS    

      4.1    PORTERS FIVE FORCES MODEL    

      4.2    BARGAINING POWER OF SUPPLIERS    

      4.3    BARGAINING POWER OF BUYERS    

      4.4    THREAT OF NEW ENTRANTS    

      4.5    THREAT OF SUBSTITUTES    

      4.6    INTENSITY OF RIVALRY    

5.    GLOBAL ERYTHROPOIETIN DRUG MARKET, BY PRODUCT

      5.1    BIOSIMILARS

      5.2    FIRST GENERATION FORMULATION

      5.3    SECOND GENERATION FORMULATION.

6.    GLOBAL ERYTHROPOIETIN DRUG MARKET, BY APPLICATION

      6.1    ONCOLOGY

      6.2    RENAL DISEASES

      6.3    HIV

      6.4    OTHER

7.    GLOBAL ERYTHROPOIETIN DRUG MARKET, BY END USER

      7.1    HOSPITALS

      7.2    PHARMACY

8.     GLOBAL ERYTHROPOIETIN DRUG MARKET, BY REGION

      8.1    INTRODUCTION

      8.2    NORTH AMERICA

            8.2.1    US

            8.2.2    CANADA

      8.3    EUROPE

            8.3.1    WESTERN EUROPE

                8.3.1.1    GERMANY

                8.3.1.2    FRANCE

                8.3.1.3    ITALY

                8.3.1.3    SPAIN

                8.3.1.5    UK

                8.3.1.6    REST OF WESTERN EUROPE

            8.3.2    EASTERN EUROPE

      8.4    ASIA

            8.4.1    JAPAN

            8.4.2    CHINA

            8.4.3    INDIA

            8.4.4    AUSTRALIA

            8.4.5    REPUBLIC OF KOREA

      8.5    REST OF ASIA-PACIFIC

      8.6    MIDDLE EAST & AFRICA

9.    COMPETITIVE LANDSCAPE    

      9.1    MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS    

            9.1.1    STRATEGIC PARTNERSHIP    

            9.1.2    MERGER & ACQUISITION    

10    COMPANY PROFILE    

      10.1    F. HOFFMANN-LA ROCHE

            10.1.1    OVERVIEW    

            10.1.2    PRODUCT OVERVIEW    

            10.1.3    FINANCIALS    

            10.1.4    KEY DEVELOPMENTS    

      10.2    JOHNSON & JOHNSON

            10.2.1    OVERVIEW    

            10.2.2    PRODUCT OVERVIEW    

            10.2.3    FINANCIALS    

            10.2.4    KEY DEVELOPMENTS    

      10.3    AMGEN

            10.3.1    OVERVIEW

            10.3.2    PRODUCT OVERVIEW    

            10.3.3    FINANCIALS

            10.3.4    STRATEGY    

            10.3.5    KEY DEVELOPMENT    

      10.4    KYOWA HAKKO KIRIN

            10.4.1    OVERVIEW

            10.4.2    PRODUCT OVERVIEW

            10.4.3    FINANCIALS

            10.4.4    KEY DEVELOPMENTS    

      10.5    TEVA PHARMACEUTICAL INDUSTRIES LTD.

            10.5.1    OVERVIEW

            10.5.2    PRODUCT OVERVIEW    

            10.5.3    FINANCIALS    

            10.5.4    KEY DEVELOPMENTS    

      10.6    OTHERS